Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Butyric acid, a short-chain fatty acid (SCFA) produced by the gut microbiota during the fermentation of dietary fibers, has attracted scientific interest for its potential role in mental health, including depression. The rationale for its use is primarily based on the gut-brain axis concept, which suggests that metabolites produced by gut bacteria can influence brain function and mood. Preclinical studies in animal models have shown that butyric acid can have anti-inflammatory effects, modulate neurotrophic factors like BDNF (Brain-Derived Neurotrophic Factor), and impact neurotransmitter systems—all of which are pathways implicated in depression. Some studies have demonstrated that oral or intraperitoneal administration of butyrate can reduce depressive-like behaviors in rodents, possibly via epigenetic mechanisms such as histone deacetylase (HDAC) inhibition that promote neuroplasticity and reduce neuroinflammation.

However, direct evidence in humans is very limited. A few small clinical studies and observational reports have linked higher levels of SCFAs, including butyrate, with better mental health outcomes, but these findings are preliminary. There are currently no large-scale, well-controlled clinical trials demonstrating that butyric acid supplementation directly alleviates depression in humans. As such, while the scientific rationale exists and animal data are promising, the strength of evidence supporting butyric acid as a treatment for depression in humans is still weak and primarily preclinical.

More about butyric acid
More about Depression

Other ingredients used for Depression

Other health conditions supported by butyric acid

Products containing butyric acid